Reducing the impact of influenza-associated secondary pneumococcal infections

Immunology and Cell Biology

Volumn 94, Issue 1, 2016, Pages 101-108

  Mifsud, Edin J ^a   Tan, Amabel C ^a   Short, Kirsty R ^a   Brown, Lorena E ^a   Chua, Brendon Y ^a   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CYSTEINE DERIVATIVE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGYLATED [2,3 BIS(PALMITOYLOXY)PROPYL]CYSTEINE; R4 [2,3 BIS(PALMITOYLOXY)PROPYL]CYSTEINE; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; CHEMOKINE; EPITOPE; LIPOPEPTIDE; MACROGOL DERIVATIVE; S-(2,3-BIS(PALMITOYLOXY)PROPYL)CYSTEINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIGEN SPECIFICITY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL PNEUMONIA; BACTERIAL TRANSMISSION; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HOST RESISTANCE; INFECTION PREVENTION; INFLAMMATION; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; MONOTHERAPY; MOUSE; NONHUMAN; RESPIRATORY SYSTEM; SECONDARY INFECTION; STREPTOCOCCUS PNEUMONIA; VIRUS IMMUNITY; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CAPILLARY PERMEABILITY; CHEMISTRY; COMPLICATION; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; METABOLISM; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PNEUMOCOCCAL INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPILLARY PERMEABILITY; CHEMOKINES; EPITOPES; FEMALE; IMMUNITY; INFLAMMATION MEDIATORS; LIPOPEPTIDES; LUNG; MICE, INBRED BALB C; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; POLYETHYLENE GLYCOLS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; VACCINATION;

EID: 84983143251     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.71     Document Type: Article

References (47)

1. McCullers JA. Insights into the Interaction between influenza virus and Pneumococcus. Clin Microbiol Rev 2006; 19: 571-582.
2. Morens David M, Taubenberger Jeffery K, Fauci Anthony S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198: 962-970.
3. Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS ONE 2009; 4: e8540.
4. Harford CG, Hara M. With the Technical Assistance of Alice H. Pulmonary edema in influenzal pneumonai of the mouse and the relation of fluid in the lungs to the inception of Pneumococcal pneumonia. J Exp Med 1950; 91: 245-260.
5. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolutionof respiratory influenza infection. J Exp Med 2008; 205: 323-329.
6. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14: 558-564.
7. Nakamura S, Davis KM, Weiser JN. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest 2011; 121: 3657-3665.
8. Sun K, Ye J, Perez DR, Metzger DW. Seasonal FluMist vaccination induces crossreactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol 2011; 186: 987-993.
9. Mina MJ, McCullers JA, Klugman KP. Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. mBio 2014; 5: e01040-13.
10. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25: 6852-6862.
11. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low-And highrisk patients. J Antimicrob Chemother 2010; 65 (Suppl 2): ii11-ii24.
12. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS ONE 2013; 8: e60348
13. Carr S, Ilyushina NA, Franks J, Adderson EE, Caniza M, Govorkova EA et al. Oseltamivir resistant influenza A and B viruses pre-And post antiviral therapy in children and young adults with cancer. Pediatr infect Dis J 2011; 30: 284-288.
14. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203: 6-10.
15. Tan ACL, Mifsud EJ, Zeng W, Edenborough K, McVernon J, Brown LE et al. Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm 2012; 9: 2710-2718.
16. Chua BY, Pejoski D, Turner SJ, Zeng W, Jackson DC. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. J Immunol 2011; 187: 1692-1701.
17. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. Induction of pro-And antiinflammatory molecules in a mouse model of Pneumococcal pneumonia after influenza. Comp Med 2007; 57: 82-89.
18. Seo S-U, Kim J-J, Yang H, Kwon H-J, Yang J-Y, Curtiss Iii R et al. Effective protection against secondary Pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice. Vaccine 2012; 30: 6816-6823.
19. Wang S, Le TQ, Kurihara N, Chida J, Cisse Y, Yano M et al. Influenza virus-cytokineprotease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis 2010; 202: 991-1001.
20. Petrache I, Birukova A, Ramirez SI, Garcia JGN, Verin AD. The role of the microtubules in tumor necrosis factor-?-induced endothelial cell permeability. Am J Respir Cell Mol Biol 2003; 28: 574-581.
21. Armstrong SM, Wang C, Tigdi J, Si X, Dumpit C, Charles S et al. Influenza infects lung microvascular endothelium leading to microvascular leak: role of apoptosis and claudin-5. PLoS ONE 2012; 7: e47323.
22. Nidavani RB, AM M, Shalawadi M. Vascular permeability and Evans blue dye: a physiological and pharmacological approach. J App Pharm Sci 2014; 4: 106-113.
23. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21: 1769-1775.
24. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-Adjuvanting immunocontraceptive vaccines. J Immunol 2002; 169: 4905-4912.
25. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101: 15440-15445.
26. Deliyannis G, Kedzierska K, Lau Yuk F, Zeng W, Turner Stephen J, Jackson David C et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 2006; 36: 770-778.
27. Cobbin JCA, Zeng W, Jackson DC, Brown LE. Different arms of the adaptive immune system induced by a combination vaccine work in concert to provide enhanced clearance of influenza. PLoS ONE 2014; 9: e115356.
28. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016-1024.
29. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkoski R, Ipe D et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127-133.
30. Heikkinen T. Influenza vaccination in the prevention of acute otitis media in children. Arch Pediatr Adolesc Med 1991; 145: 445.
31. Fedson DS, Wajda A, Nicol J, Hammond GW, Kaiser DL, Roos LL. CLinical effectiveness of influenza vaccination in manitoba. JAMA 1993; 270: 1956-1961.
32. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-784.
33. Reppe K, Tschernig T, Luhrmann A, van Laak V, Grote K, Zemlin MV et al. Immunostimulation with macrophage-Activating lipopeptide-2 increased survival in murine pneumonia. Am J Respir Cell Mol Biol 2009; 40: 474-481.
34. Baaten BJG, Clarke B, Strong P, Hou S. Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue. Vaccine 2010; 28: 4130-4137.
35. Evans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis D, Lewis RE et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 2010; 42: 40-50.
36. Lau Y-F, Tang L-H, Ooi E-E, Subbarao K. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology 2010; 406: 80-87.
37. Muñoz N, Van Maele L, Marqués JM, Rial A, Sirard J-C, Chabalgoity JA. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun 2010; 78: 4226-4233.
38. Norton EB, Clements JD, Voss TG, Cardenas-Freytag L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol 2010; 84: 2983-2995.
39. Duggan JM, You D, Cleaver JO, Larson DT, Garza RJ, Guzman Pruneda FA et al. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J Immunol 2011; 186: 5916-5926.
40. Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144-154.
41. Robinson KM, Choi SM, McHugh KJ, Mandalapu S, Enelow RI, Kolls JK et al. Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1? production in mice. J Immunol 2013; 191: 5153-5159.
42. Lee LN, Dias P, Han D, Yoon S, Shea A, Zakharov V et al. A mouse model of lethal synergism between influenza virus and Haemophilus influenzae. Am J Pathol 2010; 176: 800-811.
43. Okamoto S, Kawabata S, Nakagawa I, Okuno Y, Goto T, Sano K et al. Influenza A virusinfected hosts boost an invasive type of Streptococcus pyogenes infection in mice. J Virol 2003; 77: 4104-4112.
44. Tannock GA, Paul JA, Barry RD. Relative immunogenicity of the cold-Adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun 1984; 43: 457-462.
45. De St, Groth SF, Webster RG. Disquisition on originial antigenic sin. J Exp Med 1966; 124: 331-345.
46. Kendal AP, Pereira MS, Skehel JJ. Concepts and Procedures for Laboratory-Based Influenza Surveillance. Department of Health and Human Services Centers for Disease Control, Atlanta, GA1982.
47. Wang H-L, Lai TW. Optimization of Evans blue quantitation in limited rat tissue samples. Sci Rep 2014; 4: 6588.